NextCell Pharma (NXTCL) Q2 2026 earnings summary

Executive summary

• Launched first commercial product, NextCell-Cord RUO, in partnership with FUJIFILM Biosciences, expanding global reach.

• Strengthened presence in Asia with new office in Hong Kong and participation in EU-Japan Biotech Business Mission.

• Awaiting comprehensive data readout from ProTrans-Young clinical study in type 1 diabetes.

• Continued development of NXTCL platform and strategic rebranding of drug candidates.

Financial highlights

• Operating income for Q2 2026 was SEK 3.0 million, up from SEK 1.5 million year-over-year.

• Net income for Q2 2026 was SEK -11.7 million, compared to SEK -11.2 million in Q2 2025.

• Cash and cash equivalents at quarter-end were SEK 21.1 million, down from SEK 46.9 million a year earlier.

• Earnings per share for Q2 2026 were SEK -0.09, improved from SEK -0.13 in Q2 2025.

• Total cash flow for Q2 2026 was SEK -11.2 million, compared to SEK 24.8 million in Q2 2025.

Outlook and guidance

• Focus on commercial execution of the TD1 program and expansion of manufacturing capabilities.

• Anticipates further clinical data from ProTrans-Young to support treatment efficacy in type 1 diabetes.

• Strategy includes building international partnerships and strengthening clinical and commercial foundations.